نبذة مختصرة : Nagasaki University (長崎大学) ; 博士(医学) ; Single‑nucleotide polymorphisms (SNPs) of patatin‑like phospholipase domain‑containing 3 (PNPLA3), tolloid‑like protein 1 (TLL1) and interleukin‑28 (IL28) have been identified as susceptibility factors for liver steatosis, inflammation and fibrosis in patients with hepatitis C virus (HCV) infection. Here, whether these polymorphisms affected predispositions to changes in liver stiffness (LS) and controlled attenuation parameter (CAP) following direct‑acting antiviral (DAA) therapy was assessed. The changes in LS and steatosis in 77 HCV‑infected patients receiving DAA therapy were compared with PNPLA3, TLL1 and IL28 genotypes, using CAP, FibroScan and Virtual Touch tissue quantification (VTTQ) before treatment and 12 weeks after the end of the treatment. VTTQ results showed that LS significantly decreased in PNPLA3 CC (P=0.035), TLL1 AA (P=0.011) and IL28B TT (P=0.005) genotypes; no significant differences were observed in PNPLA3 CG/GG, TLL1 AT/TT and IL28B TG/GG. FibroScan results showed that LS significantly decreased in TLL1 AA (P=0.028) and IL28B TT (P=0.032), with no significant difference in PNPLA3 CC. No significant differences were observed in PNPLA3 CG/GG, TLL1 AT/TT and IL28B TG/GG groups. CAP was significantly increased in PNPLA3 CG/GG (P=0.039 and P<0.05) and IL28B TT (P=0.014); no significant difference was observed in PNPLA3 CC and all genotypes of TLL1 and IL28B TG/GG. Therefore, these results indicated that SNPs could predict changes in LS and steatosis after DAA therapy. ; 長崎大学学位論文 学位記番号:博(医歯薬)甲第1427号 学位授与年月日:令和4年3月18日 ; Author: Kosuke Matsumoto, Hisamitsu Miyaaki, Masanori Fukushima, Ryu Sasaki, Masafumi Haraguchi, Satoshi Miuma, Kazuhiko Nakao ; Citation: Biomedical Reports, 16(2), art.no. 9; 2022 ; Nagasaki University (長崎大学), 博士(医学) (2022-03-18) ; doctoral thesis
Processing Request
No Comments.